SEC Form 4 · accession 0000950142-17-001781

ALERE INC. · ALR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Global Pres., Cardiometabolic

Period of report

Oct 3, 2017

Accepted (ET)

Oct 3, 2017 · 5:32 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001145460

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Oct 3, 2017	D	28,298	—	D	0	D
Common Stock^F1,F4	Oct 3, 2017	D	275	—	D	0	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Employee Stock Option (Right to Buy)^F2	$19.15	Oct 3, 2017	D	10,000	D	—	—	Common Stock	10,000	D
Employee Stock Option (Right to Buy)^F2	$18.91	Oct 3, 2017	D	2,500	D	—	—	Common Stock	2,500	D
Employee Stock Option (Right to Buy)^F2	$35.58	Oct 3, 2017	D	14,709	D	—	—	Common Stock	14,709	D
Employee Stock Option (Right to Buy)^F2	$38.64	Oct 3, 2017	D	5,000	D	—	—	Common Stock	5,000	D
Employee Stock Option (Right to Buy)^F2	$26.06	Oct 3, 2017	D	40,000	D	—	—	Common Stock	40,000	D
Employee Stock Option (Right to Buy)^F2	$19.20	Oct 3, 2017	D	50,000	D	—	—	Common Stock	50,000	D
Employee Stock Option (Right to Buy)^F2	$33.73	Oct 3, 2017	D	25,000	D	—	—	Common Stock	25,000	D
Employee Stock Option (Right to Buy)^F2	$45.47	Oct 3, 2017	D	45,000	D	—	—	Common Stock	45,000	D
Employee Stock Option (Right to Buy)^F2	$38.01	Oct 3, 2017	D	15,000	D	—	—	Common Stock	15,000	D
Employee Stock Option (Right to Buy)^F2	$25.43	Oct 3, 2017	D	1,500	D	—	—	Common Stock	1,500	D
Employee Stock Option (Right to Buy)^F2	$25.68	Oct 3, 2017	D	15,000	D	—	—	Common Stock	15,000	D
Employee Stock Option (Right to Buy)^F2	$36.74	Oct 3, 2017	D	5,000	D	—	—	Common Stock	5,000	D
Restricted Stock Units^F3	—	Oct 3, 2017	D	19,470	D	—	—	Common Stock	19,470	D

F1Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").
F2Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
F3Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration.
F4These securities are owned by the Cramp Family Trust for which the reporting person and her spouse are the trustees.